Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

l results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... certain matters, including the appointment of auditors, its annual ... 2015 (the "Meeting") was adjourned, as previously disclosed on ... a.m. ( Toronto time). The date ... previous disclosed. The Meeting will reconvene at the offices ...
(Date:3/26/2015)... 26, 2015  BioNano Genomics, Inc., the leader in ... as chief commercial officer. Salyer has more than ... teams in life sciences. At BioNano, Salyer will oversee ... genome-mapping platform to assemble a comprehensive view of complex ... date, 32 institutions located in the United ...
(Date:3/26/2015)... 26, 2015 Neogen Corporation (NASDAQ: NEOG ... third quarter of fiscal 2015, which ended Feb. 28, ... year,s $6,575,000. Earnings per share in the current quarter ... year-to-date net income increased 17% over prior year to ... $0.56 per share, for the same period a year ...
(Date:3/26/2015)... 2015 ReliantHeart, Inc., an innovative supplier ... supplier of precision transit-time flow measurement solutions, are collaborating ... the efficiency of the HeartAssist5® Left Ventricular ... experience greater mobility and peace of mind. , ... board, will draw 1/6th of the power required by ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Genetics, Flurizan Will Earn a 23%,Patient Share in the United States, According ... ... Resources, WALTHAM, Mass., Feb. 5 Decision Resources, one of the,world,s ... a drug,s effect on delaying the progression,from mild cognitive impairment to Alzheimer,s ...
... Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company focused ... the chronic inflammation,underlying cardiovascular and neurological disease, today ... a Company Overview at BIO,CEO & Investor Conference ... 11:00,a.m. (ET) on Tuesday, February 12, 2008. The ...
... SOUTH SAN FRANCISCO, Calif., Feb. 5 Anesiva,Inc. (Nasdaq: ... fourth quarter,and year ended 2007 after the markets close ... teleconference at 4:30 p.m. EDT that day. Members,of Anesiva,s ... and full year 2007 as well as provide an ...
Cached Biology Technology:Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation 2
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
(Date:3/16/2015)... Germany , March 16, 2015 ... Identification Systems GmbH will present groundbreaking innovations in ... Hanover, Germany .      ... DERMALOG,s latest biometric innovation is well at the ... next generation e-gate made in Germany ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... the proteins that allow specific brain cells to "change channels," ... cell. The findings, described in the March 24 issue of ... using it to protect cells that die in Lou Gehrig's ... comes into the living room, these brain cells are able ...
... identifies a critical inhibitory step that is a ... balance between neutrophil production and destruction. The research, ... that the process for disposal of dying neutrophils ... understanding of the processes that control neutrophil turnover ...
... of the causes of child deaths to date, published ... that worldwide more than 70% of the 10.6 million ... causes: pneumonia (19%), diarrhoea (18%), malaria (8%), neonatal sepsis ... birth (8%). , Robert Black (Johns Hopkins Bloomberg School ...
Cached Biology News:Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2New Estimates For The Causes Of Child Deaths Worldwide 2
... The CHEMICON Re-Blot Plus Western Blot ... removal of antibodies from Western blots that ... iodine or other isotopes. It is not ... 4-chloronapthol, etc.), as it is not possible ...
... as a 5x solution. Designed to ... proteins without destroying antigenic binding capacity. ... signals from blots. Not recommended for ... a 5X solution sufficient to strip ...
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
Biology Products: